Ye Sun

Partner

Disclaimer

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

Ye Sun represents issuers and underwriters in the Hong Kong IPO market, particularly in the healthcare sector. He also represents issuers and underwriters in U.S. IPOs and U.S.-Hong Kong dual listings, and advises large corporations, private equity funds, and financial advisors on M&A and general corporate matters. In the past year alone, Ye has served as lead lawyer on more than a half-dozen completed IPOs and approximately twenty ongoing IPO projects. Ye is fluent in both Mandarin and English.

Languages

  • English
  • Mandarin

Admissions

  • New York

Education

  • Cornell Law School, J.D., 2011
  • Renmin University of China Law School, LL.B., 2008

Capital Markets

  • Shanghai Bio-heart Biological Technology Co., Ltd. in its US$65.3 million IPO and listing on the Hong Kong Stock Exchange
  • Yonghe Medical Group Co., Ltd. in its US$206 million IPO and listing on the Hong Kong Stock Exchange
  • Acotec Scientific Holdings Limited in its US$210 million IPO and listing on the Hong Kong Stock Exchange
  • Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited and other underwriters in the US$145 million IPO and listing of Shanghai HeartCare Medical Technology Corporation Limited on the Hong Kong Stock Exchange
  • Fortune Financial Capital as sole sponsor, Fortune Securities, CICC as joint global coordinators and other underwriters in the US$56.8 million primary listing of Zero2IPO Holdings Inc. on the Hong Kong Stock Exchange
  • J.P. Morgan, BofA Securities, CICC and Haitong International as joint sponsors and other underwriters in the approximately US$1.67 billion secondary listing of GDS Holdings Limited on the Hong Kong Stock Exchange
  • Honliv Healthcare Management Group Company Limited in its US$41.3 million IPO and listing on the Hong Kong Stock Exchange
  • Yeahka Limited in its US$212 million IPO and listing on the Hong Kong Stock Exchange
  • Peijia Medical Limited in its US$343 million IPO and listing on the Hong Kong Stock Exchange
  • Guotai Junan Capital as sole sponsor and Guotai Junan Securities (Hong Kong) as main underwriter, and other underwriters in the US$65 million IPO and listing of Zhongguancun Science-Tech Leasing on the Hong Kong Stock Exchange
  • First Shanghai Capital as sole sponsor and First Shanghai Securities as sole global coordinator, and other underwriters in the US$71 Million IPO and listing of Chen Lin Education Group on the Hong Kong Stock Exchange
  • Aesthetic Medical International Holdings in its US$34.5 million IPO on the Nasdaq
  • Inke Limited in its HK$1.05 billion IPO and listing of shares on the Hong Kong Stock Exchange
  • Goldman Sachs, Deutsche Bank and Citigroup as representatives of the underwriters in the US$44 million IPO and listing of American Depositary Shares on NASDAQ by Pintec Technology Holdings Limited
  • China International Capital Corporation, ICBC International and Macquarie as representatives of the underwriters in the HK$272 million IPO and listing of shares on the Hong Kong Stock Exchange by Wanka Online Inc.
  • Goldman Sachs, Morgan Stanley, J.P. Morgan and China Renaissance as representatives of the underwriters in the US$180 million IPO and listing of American Depositary Shares on NASDAQ by Jianpu Technology Inc.
  • 3SBio Inc. in its HK$5.5 billion IPO of shares on the Hong Kong Stock Exchange
  • Morgan Stanley, Credit Suisse, BofA Merrill Lynch and Jefferies as representatives of the underwriters in the US$362 million SEC-registered follow-on offering of common stock by China Biologic Products, Inc.
  • Zhaopin Limited in its US$75.7 million IPO and listing of its American Depositary Shares on the NYSE
  • Yirendai Limited in its US$75.0 million IPO and listing of its American Depositary Shares on NASDAQ
  • China Petrochemical Corporation in the $4.8 billion and €1.5 billion senior notes offering by one of its affiliates
  • China Petrochemical Corporation in the $6.0 billion senior notes offering by one of its affiliates
  • China Petrochemical Corporation in the $2.75 billion and €550 million senior notes offering by one of its affiliates
  • Tsinghua Unigroup Ltd. and its affiliates in their investments in a number of companies listed on the NYSE, NASDAQ, the HKEx or the LSE
  • Various companies including China Petroleum & Chemical Corporation, Sinopec Shanghai Petrochemical Company Limited, Huaneng Power International Inc., BitAuto Holdings Limited, Ozner Water International Holding Ltd, China Logistics Property Holdings Co., Ltd., and Inke Limited, in their US and/or Hong Kong securities law compliance work
  • More than ten companies in their ongoing or attempted IPOs and listings of shares on the NYSE, NASDAQ, or the Hong Kong Stock Exchange
VIEW MORE

Press Releases

In the News